Literature DB >> 18651197

Serum C-reactive protein and white blood cell count in morbidly obese surgical patients.

Sheng-Bin Chen1, Yi-Chih Lee, Kong-Han Ser, Jung-Chien Chen, Shu Chung Chen, Hsing-Fang Hsieh, Wei-Jei Lee.   

Abstract

BACKGROUND: Obesity has been widely recognized as a chronic inflammatory condition and associated with elevated inflammatory indicators including C-reactive protein (CRP) and white blood cell count (WBC). Recent studies have shown elevated CRP or WBC is a significant risk factor for cardiac events and stroke but the clinical significance of CRP and WBC has not been clearly studied in morbidly obese patients. This study is aimed at the clinical significance of WBC and CRP in morbidly obese patients and the change after bariatric surgery.
METHODS: The study was a prospectively controlled clinical study. From December 1, 2001 to January 31, 2006, of 640 (442 females and 198 males) consecutive morbid obese patients enrolled in a surgically supervised weight loss program with at least 1 year's follow-up were examined.
RESULTS: Of the patients, 476 (74.4%) had elevated CRP and 100 (15.6%) had elevated WBC at preoperative study. CRP and WBC were significantly related and both increased with increasing body mass index (BMI). CRP is also increased with increasing waist, glucose level, hemoglobin, albumin, Ca, insulin, C-peptide, and metabolic syndrome while WBC is increased with metabolic syndrome but decreased with increasing age. Multivariate analysis confirmed fasting glucose level and hemoglobin are independent predictors of the elevation of CRP while age is the only independent predictor for elevated WBC. Both WBC and CRP levels decreased rapidly after obesity surgery. These improvements resulted in a 69.8% reduction of CRP and 26.4% reduction of WBC 1 year after surgery. Although individuals who underwent laparoscopic gastric bypass lost significantly more weight (36.8 +/- 11.7 kg vs. 17.3 +/- 10.8 kg; p = 0.000) and achieved a lower BMI (27.8 +/- 4.6 vs. 35.0 +/- 5.5; p = 0.000) than individuals who underwent laparoscopic gastric banding, there was no difference in the resolution of elevated CRP 1 year after surgery (95.9% vs. 84.5%; p = 0.169) and WBC (99.4% vs. 98.3%; p = 0.323).
CONCLUSIONS: Both baseline WBC and CRP are elevated in morbid obese patients but CRP has a better clinical significance. Significant weight reduction 1 year after surgery markedly reduced CRP and WBC with a resolution rate of 93.9% and 98.2% separately. Obesity surgery performed by laparoscopic surgery is recommended for obese patients with elevated CRP or WBC.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18651197     DOI: 10.1007/s11695-008-9619-3

Source DB:  PubMed          Journal:  Obes Surg        ISSN: 0960-8923            Impact factor:   4.129


  33 in total

1.  White blood cell count and clustered features of metabolic syndrome in Japanese male office workers.

Authors:  N Nakanishi; K Suzuki; K Tatara
Journal:  Occup Med (Lond)       Date:  2002-06       Impact factor: 1.611

2.  Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001.

Authors:  Ali H Mokdad; Earl S Ford; Barbara A Bowman; William H Dietz; Frank Vinicor; Virginia S Bales; James S Marks
Journal:  JAMA       Date:  2003-01-01       Impact factor: 56.272

3.  Overweight and obesity worldwide now estimated to involve 1.7 billion people.

Authors:  Mervyn Deitel
Journal:  Obes Surg       Date:  2003-06       Impact factor: 4.129

4.  Short-term results of laparoscopic mini-gastric bypass.

Authors:  Weu Wang; Po-Li Wei; Yi-Chih Lee; Ming-Te Huang; Chong-Chi Chiu; Wei-Jei Lee
Journal:  Obes Surg       Date:  2005-05       Impact factor: 4.129

5.  Bariatric surgery: Asia-Pacific perspective.

Authors:  Wei-Jei Lee; Weu Wang
Journal:  Obes Surg       Date:  2005 Jun-Jul       Impact factor: 4.129

6.  Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery.

Authors:  Lars Sjöström; Anna-Karin Lindroos; Markku Peltonen; Jarl Torgerson; Claude Bouchard; Björn Carlsson; Sven Dahlgren; Bo Larsson; Kristina Narbro; Carl David Sjöström; Marianne Sullivan; Hans Wedel
Journal:  N Engl J Med       Date:  2004-12-23       Impact factor: 91.245

7.  Weight loss reduces C-reactive protein levels in obese postmenopausal women.

Authors:  André Tchernof; Amy Nolan; Cynthia K Sites; Philip A Ades; Eric T Poehlman
Journal:  Circulation       Date:  2002-02-05       Impact factor: 29.690

8.  C-reactive protein-mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis.

Authors:  T P Zwaka; V Hombach; J Torzewski
Journal:  Circulation       Date:  2001-03-06       Impact factor: 29.690

Review 9.  The inflammatory syndrome: the role of adipose tissue cytokines in metabolic disorders linked to obesity.

Authors:  Brent E Wisse
Journal:  J Am Soc Nephrol       Date:  2004-11       Impact factor: 10.121

10.  Can exercise training with weight loss lower serum C-reactive protein levels?

Authors:  Koichi Okita; Hirotaka Nishijima; Takeshi Murakami; Tatsuya Nagai; Noriteru Morita; Kazuya Yonezawa; Kenji Iizuka; Hideaki Kawaguchi; Akira Kitabatake
Journal:  Arterioscler Thromb Vasc Biol       Date:  2004-07-29       Impact factor: 8.311

View more
  26 in total

1.  Obesity alters the lung myeloid cell landscape to enhance breast cancer metastasis through IL5 and GM-CSF.

Authors:  Daniela F Quail; Oakley C Olson; Priya Bhardwaj; Logan A Walsh; Leila Akkari; Marsha L Quick; I-Chun Chen; Nils Wendel; Nir Ben-Chetrit; Jeanne Walker; Peter R Holt; Andrew J Dannenberg; Johanna A Joyce
Journal:  Nat Cell Biol       Date:  2017-07-24       Impact factor: 28.824

2.  Splenectomy fails to attenuate immuno-hematologic changes after rodent vertical sleeve gastrectomy.

Authors:  Alexandra R Himel; Erin B Taylor; Charles L Phillips; Bradley A Welch; Redin A Spann; Sibali Bandyopadhyay; Bernadette E Grayson
Journal:  Exp Biol Med (Maywood)       Date:  2019-06-18

3.  S100A8/A9 (Calprotectin), Interleukin-6, and C-Reactive Protein in Obesity and Diabetes before and after Roux-en-Y Gastric Bypass Surgery.

Authors:  Louise Lylloff; Lise Bathum; Sten Madsbad; Josefine Liv Gilling Grundtvig; Inge Nordgaard-Lassen; Mogens Fenger
Journal:  Obes Facts       Date:  2017-08-23       Impact factor: 3.942

Review 4.  Medical devices for the treatment of obesity.

Authors:  Phong Ching Lee; John Dixon
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-07-12       Impact factor: 46.802

5.  Impact of pathologic body composition assessed by CT-based anthropometric measurements in adult patients with multiple trauma: a retrospective analysis.

Authors:  Balázs Poros; Thomas Irlbeck; Philipp Probst; Alexander Volkmann; Philipp Paprottka; Wolfgang Böcker; Michael Irlbeck; Thomas Weig
Journal:  Eur J Trauma Emerg Surg       Date:  2019-11-19       Impact factor: 3.693

Review 6.  The immune remodel: Weight loss-mediated inflammatory changes to obesity.

Authors:  Charles L Phillips; Bernadette E Grayson
Journal:  Exp Biol Med (Maywood)       Date:  2020-01-19

7.  Metabolic syndrome and risk of breast cancer mortality by menopause, obesity, and subtype.

Authors:  Daniel T Dibaba; Kemi Ogunsina; Dejana Braithwaite; Tomi Akinyemiju
Journal:  Breast Cancer Res Treat       Date:  2018-11-21       Impact factor: 4.872

Review 8.  Lipidomic profiling at the interface of metabolic surgery and cardiovascular disease.

Authors:  Ryan H Ban; Virginia Kamvissi; Klaus-Martin Schulte; Stefan Richard Bornstein; Francesco Rubino; Juergen Graessler
Journal:  Curr Atheroscler Rep       Date:  2014-11       Impact factor: 5.113

Review 9.  Effects of lifestyle measures, antiobesity agents, and bariatric surgery on serological markers of inflammation in obese patients.

Authors:  Konstantinos Tziomalos; Hariklia V Dimitroula; Niki Katsiki; Christos Savopoulos; Apostolos I Hatzitolios
Journal:  Mediators Inflamm       Date:  2010-03-07       Impact factor: 4.711

Review 10.  Chronic inflammation in obesity and the metabolic syndrome.

Authors:  Rosário Monteiro; Isabel Azevedo
Journal:  Mediators Inflamm       Date:  2010-07-14       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.